journal
Journals Journal of Child and Adolescen...

Journal of Child and Adolescent Psychopharmacology

https://read.qxmd.com/read/38377524/-letter-to-the-editor-the-impact-of-adherence-and-cyp2c19-phenotype-on-escitalopram-exposure-in-adolescents
#21
JOURNAL ARTICLE
W Thomas Baumel, Ethan A Poweleit, Zoe Neptune, Heidi K Schroeder, Laura B Ramsey, Jeffrey Mills, Jeffrey R Strawn
No abstract text is available yet for this article.
February 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38377523/pharmacogenetics-and-oxcarbazepine-in-children-and-adolescents-beyond-hla-b-15-02
#22
REVIEW
Stephani L Stancil, Tracy Sandritter, Jeffrey R Strawn
Background: Oxcarbazepine is thought to be better-tolerated and less susceptible to drug-drug interactions than its predecessor, carbamazepine. Genetic testing for HLA-B *15:02 is recommended in specific populations to identify those at high risk of severe hypersensitivity reactions; however, other pharmacologic and pharmacogenetic factors that can impact drug disposition may be involved. Methods: We present a case of an 8-year-old boy treated with oxcarbazepine who developed drug reaction with eosinophilia and systemic symptoms (DRESS) with Stevens-Johnsons syndrome overlap and was negative for HLA-B *15:02...
February 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38377522/influence-of-cyp2d6-metabolizer-status-on-risperidone-and-paliperidone-tolerability-in-children-and-adolescents
#23
REVIEW
Amarachi A Kanu, Michelle M Johnston, Ethan A Poweleit, Samuel E Vaughn, Jeffrey R Strawn, Laura B Ramsey
Background: Risperidone and, to a lesser extent, paliperidone are metabolized by CYP2D6; however, there are limited data related to variation in CYP2D6 phenotypes and the tolerability of these medications in children and adolescents. Furthermore, the impact of CYP2D6 on the association of risperidone and paliperidone with hyperprolactinemia in youth is not well understood. Methods: A retrospective chart review was performed in psychiatrically hospitalized children and adolescents prescribed risperidone ( n  = 263, age = 3-18 years, mean age = 13 ± 3 years, 49% female) or paliperidone ( n  = 124, age = 5-18 years, mean age = 15 ± 2 years, 44% female) who had CYP2D6 genotyping performed as part of routine care...
February 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38377521/the-pharmacogenetic-journey-in-child-and-adolescent-psychopharmacology-are-we-there-yet
#24
EDITORIAL
Lisa B Namerow, Jeffrey R Strawn
No abstract text is available yet for this article.
February 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38377520/impact-of-cytochrome-p450-genetic-variation-on-patient-reported-symptom-improvement-and-side-effects-among-children-and-adolescents-treated-with-fluoxetine
#25
JOURNAL ARTICLE
Kanika Bharthi, Rayyan Zuberi, Abdullah Al Maruf, Sarker M Shaheen, Ryden McCloud, Madison Heintz, Laina McAusland, Paul D Arnold, Chad A Bousman
Background: Clinical practice guidelines recommend the use of fluoxetine, a selective serotonin reuptake inhibitor (SSRI), as a first-line pharmacotherapy for major depressive disorder (MDD) and obsessive compulsive disorder (OCD) in children and adolescents. However, response and tolerability to fluoxetine varies from child to child, which may in part, be a result of interindividual differences in fluoxetine metabolism. In this study, we examined whether genotype-predicted activity scores of cytochrome P450 enzymes were associated with patient-reported symptom improvement and side effects in children and adolescents treated with fluoxetine...
February 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38377519/acknowledgment-of-reviewers-2023
#26
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38377518/pharmacogenetic-factors-influence-escitalopram-pharmacokinetics-and-adverse-events-in-youth-with-a-family-history-of-bipolar-disorder-a-preliminary-study
#27
JOURNAL ARTICLE
Duncan C Honeycutt, Thomas J Blom, Laura B Ramsey, Jeffrey R Strawn, Kaitlyn M Bruns, Jeffrey A Welge, Luis R Patino, Manpreet K Singh, Melissa P DelBello
Introduction: Escitalopram is an effective and generally well-tolerated antidepressant, but children of parents with bipolar disorder (BD) may be at increased risk for adverse events associated with antidepressants, including increased irritability, restlessness, impulsivity, and manic symptoms. This risk may be influenced by polymorphisms in genes encoding cytochrome P450 enzymes ( CYP2C19 or CYP2D6 ), the serotonin transporter ( SLC6A4 ), and the serotonin receptor 2A subtype ( HTR2A ). We explored whether gene-drug interactions influence the emergence of adverse events in depressed and/or anxious youth with a family history of BD...
February 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38232347/response-to-pl%C3%A3-derl-et-al-re-a-multicenter-double-blind-placebo-controlled-trial-of-escitalopram-in-children-and-adolescents-with-generalized-anxiety-disorder
#28
JOURNAL ARTICLE
Jeffrey R Strawn, Jeffrey A Mills
No abstract text is available yet for this article.
January 16, 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38170185/exploring-predictors-of-ketamine-response-in-adolescent-treatment-resistant-depression
#29
JOURNAL ARTICLE
Alice Lineham, Victor J Avila-Quintero, Michael H Bloch, Jennifer Dwyer
Objective: Ketamine has proved effective as a rapid-acting antidepressant agent, but treatment is not effective for everyone (approximately a quarter to a half of patients). Some adult studies have begun to investigate predictors of ketamine's antidepressant response, but no studies have examined this in adolescents with depression. Methods: We conducted a secondary data analysis of adolescents who participated in a randomized, single-dose, midazolam-controlled crossover trial of ketamine for adolescents with treatment-resistant depression...
January 3, 2024: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38149931/from-the-editor-s-desk-progress-and-challenges-for-psychiatric-phenotypes-in-youth
#30
EDITORIAL
Paul E Croarkin
No abstract text is available yet for this article.
December 2023: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38149930/from-the-editor-in-chief-s-desk
#31
EDITORIAL
Harold S Koplewicz
No abstract text is available yet for this article.
December 2023: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38055198/efficacy-of-preventing-relapse-evaluated-by-a-multicenter-randomized-double-blind-placebo-controlled-withdrawal-study-of-escitalopram-in-japanese-adolescents-with-major-depressive-disorder
#32
RANDOMIZED CONTROLLED TRIAL
Takuya Saito, Hidetoshi Takahashi, Noa Tsujii, Tsuyoshi Sasaki, Yuta Yamaguchi, Masahiro Takatsu, Masaki Sato
Objective: To evaluate the efficacy and safety of escitalopram (ESC) in a 48-week relapse prevention study in Japanese adolescents with major depressive disorder (MDD). Methods: This was a 48-week multicenter randomized double-blind placebo-controlled parallel-group study of patients aged 12-17 years with MDD. Patients received ESC for 12 weeks as an open-label treatment period (open-label period). Patients who achieved criteria for remission or response in the open-label period received either ESC or placebo for 36 weeks as a double-blind treatment period (double-blind period)...
December 2023: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/38052059/ecological-momentary-assessment-of-youth-anxiety-evaluation-of-psychometrics-for-use-in-clinical-trials
#33
JOURNAL ARTICLE
Meghan E Byrne, Rachel A Bernstein, Daniel S Pine, Katharina Kircanski
Background: Ecological momentary assessment (EMA) captures naturalistic experience in real time and holds promise to improve our understanding and treatment of youth psychopathology. While psychometric evaluation of EMA methods is crucial, particularly for use as a tool in clinical trials, research examining the reliability and validity of EMA items in youth is lacking. Method: This study evaluates EMA responses from 204 child and adolescent participants ( M age = 12.54, 60.8% female), including 131 participants with an anxiety disorder and 73 participants with no psychiatric diagnosis...
December 2023: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/37910863/initiation-of-aripiprazole-lauroxil-long-acting-injectable-in-adolescents-during-hospitalization-a-case-series
#34
JOURNAL ARTICLE
Esther Moon, Erika Kim, Andrew Williams
Objective: The efficacy and safety of long-acting injectable (LAI) antipsychotics in the pediatric population is not well established due to limited evidence. This case series aims to describe off-label use of aripiprazole lauroxil (AL) LAI in adolescent inpatients, including findings on safety and readmission trends. Methods: This was a retrospective chart review of patients who were initiated on AL LAI while admitted at a county-based adolescent psychiatric unit between March 2021 and March 2023. Data comprised sociodemographic and clinical characteristics, such as psychiatric diagnoses, prior antipsychotic trials, and history of nonadherence...
December 2023: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/37883643/characteristic-similarities-of-irritability-between-autism-and-disruptive-mood-dysregulation-disorder
#35
JOURNAL ARTICLE
Pei-Yin Pan, Chin-Bin Yeh
Objective: Irritability in children with autism spectrum disorder (ASD) is prominent and often leads to distress to both autistic children and their families. However, the nature of irritability in autism and the difference from nonautistic children have rarely been examined. This study aimed to investigate the clinical characteristics of irritability in autism, and to compare the symptom profiles with those of disruptive mood dysregulation disorder (DMDD) in nonautistic children. Methods: Fifty-six children aged 7-17 years (mean age 10...
December 2023: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/37870770/co-occurring-anxiety-in-youth-with-tic-disorders-a-review
#36
REVIEW
Yelizaveta Sapozhnikov, Jennifer Vermilion
Objective: To review the current state of the literature regarding anxiety symptoms and anxiety disorders in chronic tic disorder (CTD). Results: We conducted a literature search on anxiety and tic disorders. Anxiety symptoms and anxiety disorders are common in youth with CTD, with ∼30%-50% of youth with CTD having at least one co-occurring anxiety disorder. Tics often improve by young adulthood but anxiety symptoms tend to persist, or worsen, over time. Anxiety and tics are closely related, but the exact nature of their relationship is poorly understood...
December 2023: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/37966364/growth-trajectories-in-stimulant-treated-children-and-adolescents-a-qualitative-review-of-the-literature-from-comprehensive-datasets-and-registries
#37
REVIEW
Chloe Hutt Vater, Joseph Biederman, Maura DiSalvo, Hannah O'Connor, Haley Parker, K Yvonne Woodworth, Janet Wozniak, Stephen V Faraone
Objective: Attention-deficit/hyperactivity disorder (ADHD) treatment with stimulant products has been shown to be safe and effective; however, there are remaining concerns about their possible adverse effects on growth trajectories. We conducted a systematic review of the extant literature derived from ecologically valid databases and registries to assess the body of knowledge about the effects of stimulants on growth trajectories in naturalistic samples. Methods: Using PubMed and PsycINFO, we searched for articles published before February 8, 2023 that focused on growth findings associated with stimulant treatment in pediatric ADHD from comprehensive datasets derived from naturalistic population studies...
November 2023: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/37966363/caregiver-burden-stress-and-relationship-cohesion-among-self-identified-caregivers-of-children-with-pediatric-acute-onset-neuropsychiatric-syndrome
#38
JOURNAL ARTICLE
Janice T Tona, Julie Ash, Emily Brown, Courtney Campagna, Kellie Kostek, Erin Lawton, Andrea Rieth, Machiko Tomita
Objective: Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) experience sudden onset neuropsychiatric symptoms after infection or other triggers. Symptoms range from mild to severe, potentially lasting days, weeks, months, or longer. Exacerbation-related functional decline presents in many aspects of daily life, generally accompanied by family stress and caregiver burden. We sought to investigate the relationship between severity of PANS symptoms and caregiver burden/stress and the relationship between severity of PANS symptoms and degree of caregiver/child cohesion...
November 2023: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/37966362/from-the-editors-desk
#39
EDITORIAL
Ronald J Steingard, Paul E Croarkin
No abstract text is available yet for this article.
November 2023: Journal of Child and Adolescent Psychopharmacology
https://read.qxmd.com/read/37966361/understanding-and-managing-new-onset-homicidal-ideation-in-an-adolescent-with-depression
#40
JOURNAL ARTICLE
Keneil Brown, Yasin Bez, Kathy Truong, Manya Saaraswat, Barbara J Coffey
No abstract text is available yet for this article.
November 2023: Journal of Child and Adolescent Psychopharmacology
journal
journal
20144
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.